ORIC Pharmaceuticals Reports 35% ORR in HER2 Mutation Patients from Enozertinib Trial
Written by Emily J. Thompson, Senior Investment Analyst
Source: Newsfilter
Updated: 51 minutes ago0mins
- Promising Trial Results: ORIC Pharmaceuticals' enozertinib (ORIC-114) demonstrated a 35% objective response rate (ORR) in previously treated NSCLC patients with HER2 exon 20 mutations during the Phase 1b trial, indicating its potential in treating resistant cancers.
- Good Safety Profile: The drug exhibited a manageable safety profile with mostly Grade 1 or 2 treatment-related adverse events, and only two patients discontinued treatment due to adverse events, highlighting its acceptability in clinical use.
- Enrollment Completed: As of the August 29, 2025 cutoff, 49 patients were enrolled, with 47% having baseline brain metastases, suggesting the drug's applicability in complex cases.
- Future Development Plans: ORIC plans to use the 80 mg dose for potential Phase 3 development, continuing enrollment and follow-up in EGFR mutation patients, with further updates expected in mid-2026, demonstrating the company's commitment to future clinical advancements.
ORIC.O
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on ORIC
Wall Street analysts forecast ORIC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ORIC is 19.10 USD with a low forecast of 15.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
11 Buy
1 Hold
0 Sell
Strong Buy
Current: 10.980
Low
15.00
Averages
19.10
High
25.00
Current: 10.980
Low
15.00
Averages
19.10
High
25.00
Goldman Sachs
initiated
2025-12-04
New
Reason
Goldman Sachs
Price Target
2025-12-04
New
initiated
Reason
Goldman Sachs initiated coverage of Oric Pharmaceuticals with an Early Stage Biotech rating. Oric is a clinical stage biotechnology company with a pipeline of oncology candidates focused on addressing resistance in cancer, the analyst tells investors in a research note.
Evercore ISI
Cory Kasimov
Outperform
initiated
$25
2025-11-20
Reason
Evercore ISI
Cory Kasimov
Price Target
$25
2025-11-20
initiated
Outperform
Reason
Evercore ISI analyst Cory Kasimov initiated coverage of Oric Pharmaceuticals with an Outperform rating and $25 price target. The firm sees a "compelling" opportunity for the company in the "large" prostate cancer market. Oric's lead asset ORIC-944 has the potential to bring a highly effective oral agent across multiple settings, the analyst tells investors in a research note.
JPMorgan
Anupam Rama
maintain
$17 -> $20
2025-11-18
Reason
JPMorgan
Anupam Rama
Price Target
$17 -> $20
2025-11-18
maintain
Reason
JPMorgan analyst Anupam Rama raised the firm's price target on Oric Pharmaceuticals to $20 from $17 and keeps an Overweight rating on the shares. The firm adjusted models in the smid-cap biotech space.
Wolfe Research
Kalpit Patel
Peer Perform
initiated
2025-11-17
Reason
Wolfe Research
Kalpit Patel
Price Target
2025-11-17
initiated
Peer Perform
Reason
Wolfe Research analyst Kalpit Patel initiated coverage of Oric Pharmaceuticals with a Peer Perform rating and no price target. The firm highlights the baseline imbalance in Pfizer's (PFE) mevro study and thinks that the magnitude of benefit may be overstated with the PRC2 inhibitor drug class.
See All Ratings
About ORIC
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on improving patients’ lives by Overcoming Resistance In Cancer. The Company is advancing a diverse pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. The Company's clinical-stage product candidates include ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-114, a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers. In addition, the Company is also developing multiple discovery stage precision medicines targeting other hallmark cancer resistance mechanisms. Its out-licensing candidates include ORIC-533 and ORIC-613.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
How did the company's recent strategic decisions impact its latest financial performance?
Can you explain the factors behind the recent changes in the company's stock price?
What are the expected impacts of current market trends on the company's future growth?
Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?